SynthesisClinical and translational gastroenterology2026
Global Prevalence of Functional Constipation Across All Age Groups According to Rome II-IV Criteria, 1999-2025: A Systematic Review and Meta-Analysis.
Synthesis in Clinical and translational gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Teaching stool form recognition in primary school: multimedia versus paper-based instruction using the Bristol stool form scale.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
introductionThe most recent global estimates of functional constipation (FC) were reported in 2020 for adults and in 2017 for children; however, no comprehensive update encompassing all age groups has been published since then. Thus, we aimed to provide an updated, standardized global estimate of FC prevalence across all age groups using the Rome criteria.
methodsWe systematically searched PubMed/MEDLINE, Embase, CINAHL, and Cochrane Library, from inception to March 28, 2025, for population-based observational studies reporting FC prevalence according to Rome II, III, or IV criteria. Eligible studies included cross-sectional or prospective designs involving children, adults, or older population. Studies without Rome-based definitions, extractable prevalence data, or population-based sampling were excluded. The primary outcome was pooled prevalence of FC. Subgroup analyses were performed by Rome version, diagnostic method, geographic region, age, sex, and behavioral factors.
resultsFrom 12,574 identified records, a total of 128 studies from 44 countries comprising 459,061 participants met inclusion criteria. The global pooled prevalence of FC was 12.14% (95% CI, 11.14-13.23; I 2 = 98.99%). Prevalence was higher in female patients (14.60% [12.50-17.04]; I 2 = 99.01%) than male patients (10.62% [8.84-12.75]; I 2 = 98.74%). By age, prevalence was highest in older population (19.89% [95% CI, 14.67-26.97]; I 2 = 98.77%), followed by children (12.06% [11.05-13.16]; I 2 = 97.85%) and adults (9.50% [8.11-11.14]; I 2 = 99.12%). The pooled prevalence was highest with Rome II (12.68% [95% CI, 8.02-20.04]; I 2 = 99.31%) and lowest with Rome IV (10.34% [9.11-11.75]; I 2 = 98.79%). DISCUSSION: FC is a highly prevalent global disorder, with substantial variation by age, sex, diagnostic criteria, country, and region. Standardized population-based assessments using validated Rome criteria are essential to inform clinical practice and public health strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.